"Two sessions" hot discussion: the inclusion of medicare reimbursement of innovative drugs, why not in the hospital to buy?

544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">，、？544px;text-align:right;text-indent:28px;">，、？544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">2021544px;text-align:right;text-indent:28px;">“”。544px;text-align:right;text-indent:28px;">，“”：544px;text-align:right;text-indent:28px;">“，，，；544px;text-align:right;text-indent:28px;">，，。544px;text-align:right;text-indent:28px;">”
544px;text-align:right;text-indent:28px;">2021544px;text-align:right;text-indent:28px;">“”。544px;text-align:right;text-indent:28px;">，“”：544px;text-align:right;text-indent:28px;">“，，，；544px;text-align:right;text-indent:28px;">，，。544px;text-align:right;text-indent:28px;">”
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">，“”，“”。“”，、、、，“”，、。544px;text-align:right;text-indent:28px;">However, at this year's national "two sessions", "difficulty in hospital admission of innovative drugs" is still the focus of attention of representatives from the medical and health sector.
Many representative members of the "Two Sessions", including Wang Jianye, former president of Beijing Hospital, Yao Shukun, former vice president of China-Japan Friendship Hospital, Sun Piaoyang, chairman of Jiangsu Hengrui Pharmaceutical Group Co.
, Ltd.
, and Li Yan, president of Qilu Pharmaceutical, were all544px;text-align:right;text-indent:28px;"> in the proposal.
544px;text-align:right;text-indent:28px;">It is said that the problem of "last mile" of hospital admission for innovative drugs should be solved as soon as possible, so that patients can use urgently needed new drugs and good drugs more quickly.
They all talked about the need to solve the "last mile" problem of innovative drugs in hospitals as soon as possible, so that patients can quickly use new and good drugs that are urgently needed in clinical practice.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Not long ago, a news report showed that a patient in Jiangsu found that following the doctor’s “instructions”, he paid more than 500,000 yuan and bought the medicines from an out-of-hospital pharmacy that was wholly owned by the hospital and located in the lobby on the first floor of the outpatient clinic.
In the medical insurance catalog.
The patient took the hospital to court and rushed to the hot search.
544px;text-align:right;text-indent:28px;">Not long ago, a news report showed that a patient in Jiangsu found that following the doctor’s “instructions”, he paid more than 500,000 yuan and bought the medicines from an out-of-hospital pharmacy that was wholly owned by the hospital and located in the lobby on the first floor of the outpatient clinic.
In the medical insurance catalog.
The patient took the hospital to court and rushed to the hot search.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">It is clearly a medicine in the medical insurance reimbursement catalog.
Why can't I buy it in the hospital? I have to buy it at my own pharmacy? Why are the innovative drugs that have been heavily bargained through the national medical insurance negotiations so long to land in hospitals? A series of issues have also triggered heated discussions in the society.
On the eve of the "Two Sessions", at the "Closed-door Symposium on Exploring the Access Mechanism of Innovative Medicines" organized by Caijian magazine Caijiandao, a number of well-known experts and scholars in the medical and health industry conducted in-depth discussions on this.
544px;text-align:right;text-indent:28px;">It is clearly a medicine in the medical insurance reimbursement catalog.
Why can't I buy it in the hospital? I have to buy it at my own pharmacy? Why are the innovative drugs that have been heavily bargained through the national medical insurance negotiations so long to land in hospitals? A series of issues have also triggered heated discussions in the society.
On the eve of the "Two Sessions", at the "Closed-door Symposium on Exploring the Access Mechanism of Innovative Medicines" organized by Caijian magazine Caijiandao, a number of well-known experts and scholars in the medical and health industry conducted in-depth discussions on this.
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;text-indent:0em;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>011406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">
011406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">
011406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">5px;background:#FFFFFF;transform:rotate(0deg);text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>To improve the availability of innovative drugs, the problem is stuck in the "last mile"To improve the availability of innovative drugs, the problem is stuck in the "last mile"544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">In recent years, my country has made a lot of efforts to solve the problem of "difficult and expensive medical treatment".
Especially in terms of medical innovation: The innovative drug priority review and approval system implemented by the National Medical Products Administration has greatly accelerated the launch of new drugs; and since the establishment of the National Medical Insurance Administration, the medical insurance catalogue has not been adjusted for many years and the adjustment time has been irregular.
In a negotiation, innovative drugs with high clinical value were included in medical insurance at an ultra-low price reduction, which significantly reduced the burden on patients and medical insurance fund expenditures.
544px;text-align:right;text-indent:28px;">In recent years, my country has made a lot of efforts to solve the problem of "difficult and expensive medical treatment".
Especially in terms of medical innovation: The innovative drug priority review and approval system implemented by the National Medical Products Administration has greatly accelerated the launch of new drugs; and since the establishment of the National Medical Insurance Administration, the medical insurance catalogue has not been adjusted for many years and the adjustment time has been irregular.
In a negotiation, innovative drugs with high clinical value were included in medical insurance at an ultra-low price reduction, which significantly reduced the burden on patients and medical insurance fund expenditures.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">According to statistics, only counting chemical drugs and biological products, a total of 35 Class 1 new drugs were approved for marketing in the three years from 2018 to 2020, 19 of which have been included in the national medical insurance catalog, accounting for more than 54%, and from approval to being included in medical insurance The interval has been gradually shortened from 1-2 years to about half a year.
544px;text-align:right;text-indent:28px;">According to statistics, only counting chemical drugs and biological products, a total of 35 Class 1 new drugs were approved for marketing in the three years from 2018 to 2020, 19 of which have been included in the national medical insurance catalog, accounting for more than 54%, and from approval to being included in medical insurance The interval has been gradually shortened from 1-2 years to about half a year.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">However, as experienced by Jiangsu patients in the previous article, it is still common that high-priced “life-saving medicines” are included in medical insurance but cannot be purchased in hospitals.
They can only be purchased at their own pharmacies.
According to the statistics of 1420 sample hospitals of the Chinese Pharmaceutical Association, less than 20% of the oncology innovative drugs included in the National Medical Insurance Catalogue in 2018 have been admitted to the hospital by the end of 2019.
As of the third quarter of 2020, only about 25% of the types of medical insurance included in 2019 have been admitted to the hospital, and 75% of hospital patients cannot obtain regular prescriptions from the hospital.
544px;text-align:right;text-indent:28px;">However, as experienced by Jiangsu patients in the previous article, it is still common that high-priced “life-saving medicines” are included in medical insurance but cannot be purchased in hospitals.
They can only be purchased at their own pharmacies.
According to the statistics of 1420 sample hospitals of the Chinese Pharmaceutical Association, less than 20% of the oncology innovative drugs included in the National Medical Insurance Catalogue in 2018 have been admitted to the hospital by the end of 2019.
As of the third quarter of 2020, only about 25% of the types of medical insurance included in 2019 have been admitted to the hospital, and 75% of hospital patients cannot obtain regular prescriptions from the hospital.
544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;box-sizing:border-box ;overflow-wrap:break-word ;">Photo/Data from the 1,420 sample hospitals of the Chinese Pharmaceutical Association (CPA) negotiating drug admissions544px;text-align:right;text-indent:28px;box-sizing:border-box ;overflow-wrap:break-word ;">Photo/Data from the 1,420 sample hospitals of the Chinese Pharmaceutical Association (CPA) negotiating drug admissions544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">CPPCC National Committee 544px;text-align:right;text-indent:28px;">members 544px;text-align:right;text-indent:28px;">, the Friends of 544px;text-align:right;text-indent:28px;">good hospital Former Vice hospital 544px;text-align:right;text-indent:28px;">long Alcoholism & two this year 544px;text-align:right;text-indent:28px;">at the meeting 544px;text-align:right;text-indent:28px;">, submitted a "smooth flow of institutional mechanisms for rapid access to medical class of drugs, the patient is recommended to improve accessibility of.
" 544px;text-align:right;text-indent:28px;">He found that among those drugs that “have been covered by medical insurance but cannot enter the hospital”, there are many Class 1 new drugs among them.
544px;text-align:right;text-indent:28px;">Category 1 new drugs refer to innovative drugs (including chemical drugs, traditional Chinese medicines and biological products) that have not been marketed at the registration application stage at home or abroad.
They are often urgently needed clinically needed "life-saving drugs" and are also core pharmaceutical technologies, including many Domestic innovative drugs with better safety and efficacy, and prices far lower than imported drugs.
544px;text-align:right;text-indent:28px;">This makes the inclusion of "life-saving medicine" in medical insurance a futile, and medical insurance negotiations have gone through the stage.
544px;text-align:right;text-indent:28px;">CPPCC National Committee 544px;text-align:right;text-indent:28px;">members 544px;text-align:right;text-indent:28px;">, the Friends of 544px;text-align:right;text-indent:28px;">good hospital Former Vice hospital 544px;text-align:right;text-indent:28px;">long Alcoholism & two this year 544px;text-align:right;text-indent:28px;">at the meeting 544px;text-align:right;text-indent:28px;">, submitted a "smooth flow of institutional mechanisms for rapid access to medical class of drugs, the patient is recommended to improve accessibility of.
" 544px;text-align:right;text-indent:28px;">He found that among those drugs that “have been covered by medical insurance but cannot enter the hospital”, there are many Class 1 new drugs among them.
544px;text-align:right;text-indent:28px;">Category 1 new drugs refer to innovative drugs (including chemical drugs, traditional Chinese medicines and biological products) that have not been marketed at the registration application stage at home or abroad.
They are often urgently needed clinically needed "life-saving drugs" and are also core pharmaceutical technologies, including many Domestic innovative drugs with better safety and efficacy, and prices far lower than imported drugs.
544px;text-align:right;text-indent:28px;">This makes the inclusion of "life-saving medicine" in medical insurance a futile, and medical insurance negotiations have gone through the stage.
544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;box-sizing:border-box ;overflow-wrap:break-word ;">Photo/Yao Shukun, member of the National Committee of the Chinese People's Political Consultative Conference and former vice president of China-Japan Friendship Hospital, spoke at the symposium544px;text-align:right;text-indent:28px;box-sizing:border-box ;overflow-wrap:break-word ;">Photo/Yao Shukun, member of the National Committee of the Chinese People's Political Consultative Conference and former vice president of China-Japan Friendship Hospital, spoke at the symposium544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">The patient's feelings are more direct.
A PD-1/PD-L1 drug patient survey report initiated by Dongdong Oncology Department and analyzed by BenHealth Consulting shows that among the 353 questionnaires (as of February 18, 2021) in 26 provinces across the country, there are still three major Difficulties make the use of PD-(L)1 seem "desirable":544px;text-align:right;text-indent:28px;">The patient's feelings are more direct.
A PD-1/PD-L1 drug patient survey report initiated by Dongdong Oncology Department and analyzed by BenHealth Consulting shows that among the 353 questionnaires (as of February 18, 2021) in 26 provinces across the country, there are still three major Difficulties make the use of PD-(L)1 seem "desirable":544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">1.
87% of respondents believe that the cost of PD-1/PD-L1 immunotherapy is too high and the economic burden is heavy;544px;text-align:right;text-indent:28px;">1.
87% of respondents believe that the cost of PD-1/PD-L1 immunotherapy is too high and the economic burden is heavy;544px;text-align:right;text-indent:28px;"> 1.
87% of respondents believe that the cost of PD-1/PD-L1 immunotherapy is too high, Heavy economic burden;544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">2.
62% of the interviewees believed that medicines prescribed by doctors were not available in hospitals, which affected their use in hospitals;544px;text-align:right;text-indent:28px;">2.
62% of the interviewees think that the medicines prescribed by doctors cannot be bought in the hospital, which affects their use in the hospital;544px;text-align:right;text-indent:28px;"> 2.
62% of the interviewees think that the medicines prescribed by the doctors cannot be bought in the hospital, which affects their use in the hospital;544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">3.
43% of the respondents believe that the medicines they want to use cannot be bought in the treatment hospitals, and they can only choose the medicines that the hospital has.
544px;text-align:right;text-indent:28px;">3.
43% of the respondents believe that the medicines they want to use cannot be bought in the treatment hospitals, and they can only choose the medicines that the hospital has.
544px;text-align:right;text-indent:28px;">3.
43% of the respondents believe that the medicines they want to use cannot be bought in the treatment hospitals, and they can only choose the medicines that the hospital has.
544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">In this survey, the cost of PD-1/PD-L1 treatment for the interviewed patients is relatively high, with an average treatment cost of 127,000 yuan, and currently all interviewed patients are unable to receive medical insurance reimbursement, and only some patients can use commercial Insurance is reimbursed.
544px;text-align:right;text-indent:28px;">In this survey, the cost of PD-1/PD-L1 treatment for the interviewed patients is relatively high, with an average treatment cost of 127,000 yuan, and currently all interviewed patients are unable to receive medical insurance reimbursement, and only some patients can use commercial Insurance is reimbursed.
544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Not only that, 544px;text-align:right;text-indent:28px;">64% of respondents buy PD-1/PD-L1 drugs outside the hospital, but because they need to be injected, they have to be used in the hospital.
In this process, it is also necessary to ensure harsh transportation and storage conditions.
It has become a risk that many patients worry about, and it also brings many inconveniences.
544px;text-align:right;text-indent:28px;">More 81% 544px;text-align:right;text-indent:28px;">of respondents patient table 544px;text-align:right;text-indent:28px;">shows, the most anticipated shopping channels hospital. 544px;text-align:right;text-indent:28px;">Not only that, 544px;text-align:right;text-indent:28px;">64% of respondents buy PD-1/PD-L1 drugs outside the hospital, but because they need to be injected, they have to be used in the hospital.
In this process, it is also necessary to ensure harsh transportation and storage conditions.
It has become a risk that many patients worry about, and it also brings many inconveniences.
544px;text-align:right;text-indent:28px;">More 81% 544px;text-align:right;text-indent:28px;">of respondents patient table 544px;text-align:right;text-indent:28px;">shows, the most anticipated shopping channels hospital. 544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">These data show that "achieving hospital access as soon as possible and making it available to patients" has become the key to my country's current support for medical innovation and improving patient satisfaction.
544px;text-align:right;text-indent:28px;">These data show that "achieving hospital access as soon as possible and making it available to patients" has become the key to my country's current support for medical innovation and improving patient satisfaction.
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;text-indent:0em;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>021406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">
021406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">
021406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">5px;background:#FFFFFF;transform:rotate(0deg);text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>Why is it so difficult for innovative drugs to be admitted to the hospital? Hospital: I can't tell if there is sufferingWhy is it so difficult for innovative drugs to be admitted to the hospital? Hospital: I can't tell if there is suffering544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">While the admission of innovative drugs is difficult to be criticized, the unspeakable hidden behind the introduction of drugs in hospitals have also surfaced, including the assessment pressure of "drug share" in public hospitals, and restrictions on the number of drugs admitted by hospitals.
544px;text-align:right;text-indent:28px;">While the admission of innovative drugs is difficult to be criticized, the unspeakable hidden behind the introduction of drugs in hospitals have also surfaced, including the assessment pressure of "drug share" in public hospitals, and restrictions on the number of drugs admitted by hospitals.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Some hospitals have complained about their complaints: The current public hospitals’ performance appraisal indicators have clear regulations on drug product regulations: tertiary hospitals ≤ 1500; second-level hospitals ≤ 1200.
If innovative drugs want to come in, they must "kick out" other existing drugs, which naturally directly restricts the admission of new drugs to hospitals.
544px;text-align:right;text-indent:28px;">Some hospitals have complained about their complaints: The current public hospitals’ performance appraisal indicators have clear regulations on drug product regulations: tertiary hospitals ≤ 1500; second-level hospitals ≤ 1200.
If innovative drugs want to come in, they must "kick out" other existing drugs, which naturally directly restricts the admission of new drugs to hospitals.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">It is understood that this regulation was issued by the former General Office of the Ministry of Health in 2011, and it may not conform to the law of medical development in the new era.
Especially with the development of precision diagnosis and treatment, only one disease of lung cancer can be subdivided into multiple subtypes.
The treatment measures for each subtype of lung cancer are different.
According to the different stages of treatment of patients, all drugs can be divided into 1 Line/2 line/3 line treatment.
Only with the right medicine can precise treatment be achieved.
544px;text-align:right;text-indent:28px;">It is understood that this regulation was issued by the former General Office of the Ministry of Health in 2011, and it may not conform to the law of medical development in the new era.
Especially with the development of precision diagnosis and treatment, only one disease of lung cancer can be subdivided into multiple subtypes.
The treatment measures for each subtype of lung cancer are different.
According to the different stages of treatment of patients, all drugs can be divided into 1 Line/2 line/3 line treatment.
Only with the right medicine can precise treatment be achieved.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">But the relevant state departments are not without action.
As a matter of fact, from the General Office of the State Council to the National Health Commission, the competent department of medical institutions, there have been multiple regulations to encourage clinically urgently needed innovative drugs, especially drugs that have passed national medical insurance negotiations, to land in hospitals as soon as possible.
544px;text-align:right;text-indent:28px;">But the relevant state departments are not without action.
As a matter of fact, from the General Office of the State Council to the National Health Commission, the competent department of medical institutions, there have been multiple regulations to encourage clinically urgently needed innovative drugs, especially drugs that have passed national medical insurance negotiations, to land in hospitals as soon as possible.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">At the beginning of 2019, the General Office of the State Council issued the "Opinions on Strengthening the Performance Appraisal of Tertiary Public Hospitals", proposing to "replace the appraisal of the proportion of drugs with rational drug use indicators".
The National Health Commission has also issued a document clearly stating that “hospitals shall not use the total control of medical expenses, the total control of medical insurance expenses, the proportion of medicines and the restriction on the number of types of medicines, etc.
, to influence the supply guarantee and rational use of medicines in the negotiation”, and will The "National Medical Insurance Negotiation Access Drug Provision and Use Status" is included in the assessment of designated medical institutions for medical insurance.
544px;text-align:right;text-indent:28px;">At the beginning of 2019, the General Office of the State Council issued the "Opinions on Strengthening the Performance Appraisal of Tertiary Public Hospitals", proposing to "replace the appraisal of the proportion of drugs with rational drug use indicators".
The National Health Commission has also issued a document clearly stating that “hospitals shall not use the total control of medical expenses, the total control of medical insurance expenses, the proportion of medicines and the restriction on the number of types of medicines, etc.
, to influence the supply guarantee and rational use of medicines in the negotiation”, and will The "National Medical Insurance Negotiation Access Drug Provision and Use Status" is included in the assessment of designated medical institutions for medical insurance.
"Hospitals shall not use the total control of medical expenses, the total control of medical insurance costs, the proportion of drugs and the restriction on the number of drugs to influence the supply guarantee and rational use of drugs for the negotiation of drugs", and the "National Medical Insurance Negotiation Access Drugs are equipped and used" Situation" is included in the assessment of medical insurance designated medical institutions.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">However, the reality is that it seems that only a few regions such as Sichuan and Chongqing have issued corresponding local policies, including the provision of "National Talks" drugs as one of the hospital assessment indicators, while most hospitals in other regions of the country have not implemented it.
The above new regulations.
544px;text-align:right;text-indent:28px;">However, the reality is that it seems that only a few regions such as Sichuan and Chongqing have issued corresponding local policies, including the provision of "National Talks" drugs as one of the hospital assessment indicators, while most hospitals in other regions of the country have not implemented it.
The above new regulations.
544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;box-sizing:border-box ;overflow-wrap:break-word ;">Photo/Regulations on the provision of medicines for medical insurance negotiations in the assessment indicators of medical institutions in Chongqing544px;text-align:right;text-indent:28px;box-sizing:border-box ;overflow-wrap:break-word ;">Photo/Regulations on the provision of medicines for medical insurance negotiations in the assessment indicators of medical institutions in Chongqing544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Why is it so difficult for innovative drugs to be admitted to the hospital? To further explore the root cause, a number of hospital administrators and clinical experts mentioned a key word in the symposium—"zero drug add-on".
544px;text-align:right;text-indent:28px;">544px;text-align:right;text-indent:28px;">Why is it so difficult for innovative drugs to be admitted to the hospital? To further explore the root cause, a number of hospital administrators and clinical experts mentioned a key word in the symposium—"zero drug add-on".
544px;text-align:right;text-indent:28px;">Why is it so difficult for innovative drugs to be admitted to the hospital? To further explore the root cause, a number of hospital administrators and clinical experts mentioned a key word in the symposium—"zero drug add-on".
544px;text-align:right;text-indent:28px;">544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">After the start of the "new medical reform" in 2009, in order to eradicate the chronic diseases of using medicines to nourish doctors and high prices of medicines, local governments have gradually cancelled the 15% drug purchase price markup in public hospitals, which is what the industry often calls "zero markup for medicines.
" .
This reform policy caused a lot of controversy when it was introduced at that time, but it is hard to imagine that it still has a non-negligible impact on the operation of the medical and health system even more than a decade later.
544px;text-align:right;text-indent:28px;">After the start of the "new medical reform" in 2009, in order to eradicate the chronic diseases of using medicines to nourish doctors and high prices of medicines, local governments have gradually cancelled the 15% drug purchase price markup in public hospitals, which is what the industry often calls "zero markup for medicines.
" .
This reform policy caused a lot of controversy when it was introduced at that time, but it is hard to imagine that it still has a non-negligible impact on the operation of the medical and health system even more than a decade later.
544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Photo 544px;text-align:right;text-indent:28px;">: Zhang Yan, director of the Department of Pharmacy of Beijing Tongren Hospital, speaks at the symposium
544px;text-align:right;text-indent:28px;">Photo 544px;text-align:right;text-indent:28px;">: Zhang Yan, director of the Department of Pharmacy of Beijing Tongren Hospital, speaks at the symposium
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">"In the original 15% of the drug additions, it was not entirely the profit income of the hospital.
The cost of pharmacy services accounted for 4%-6%.
Because the hospital's medicine intake, storage, dispensing, patient education, pharmacy clinics, medication consultation, Difficult case consultations, etc.
, all require manpower and material resources, which need to be borne by the hospital itself.
” said Zhang Yan, director of the Department of Pharmacy of Beijing Tongren Hospital.
544px;text-align:right;text-indent:28px;">"In the original 15% of the drug additions, it was not entirely the profit income of the hospital.
The cost of pharmacy services accounted for 4%-6%.
Because the hospital's medicine intake, storage, dispensing, patient education, pharmacy clinics, medication consultation, Difficult case consultations, etc.
, all require manpower and material resources, which need to be borne by the hospital itself.
” said Zhang Yan, director of the Department of Pharmacy of Beijing Tongren Hospital.
544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Photo 544px;text-align:right;text-indent:28px;">: Wang Jianye, member of the National Committee of the Chinese People's Political Consultative Conference and former president of Beijing Hospital, delivered a speech at the symposium544px;text-align:right;text-indent:28px;">544px;text-align:right;text-indent:28px;">Photo 544px;text-align:right;text-indent:28px;">: Wang Jianye, member of the National Committee of the Chinese People's Political Consultative Conference and former president of Beijing Hospital, delivered a speech at the symposium544px;text-align:right;text-indent:28px;">544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Wang Jianye, a member of the National Committee of the Chinese People's Political Consultative Conference and the former president of Beijing Hospital, also stated that, taking Beijing Hospital as an example, the annual fixed cost of the entire pharmacy department is around 50 million yuan.
Without the drug bonus, the hospital cannot pay for it.
The more drugs it sells, the greater the cost and the more it loses.
Therefore, the hospital has no incentive to purchase drugs, especially expensive innovative drugs.
.
After many hospitals implemented the zero mark-up rate policy for local drugs, the drug catalogues for clinical use became "only out but not in", and hospital pharmacy management committees no longer held regularly.
544px;text-align:right;text-indent:28px;">Wang Jianye, a member of the National Committee of the Chinese People's Political Consultative Conference and the former president of Beijing Hospital, also stated that, taking Beijing Hospital as an example, the annual fixed cost of the entire pharmacy department is around 50 million yuan.
Without the drug bonus, the hospital cannot pay for it.
The more drugs it sells, the greater the cost and the more it loses.
Therefore, the hospital has no incentive to purchase drugs, especially expensive innovative drugs.
.
After many hospitals implemented the zero mark-up rate policy for local drugs, the drug catalogues for clinical use became "only out but not in", and hospital pharmacy management committees no longer held regularly.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">It is understood that any medicine that wants to enter a hospital for purchase must be approved by the hospital's pharmacy committee.
The frequency of regular meetings of the Pharmaceutical Affairs Committee determines how quickly new drugs enter the hospital 544px;text-align:right;text-indent:28px;">pharmacy 544px;text-align:right;text-indent:28px;">.
However, at present, most hospitals hold pharmacy meetings very frequently, generally once a year or once every six months.
This means that some of the negotiated drugs have passed the negotiation agreement period before they enter the hospital smoothly (the validity period of each negotiation of the National Medical Insurance Catalog is 2 years).
544px;text-align:right;text-indent:28px;">It is understood that any medicine that wants to enter a hospital for purchase must be approved by the hospital's pharmacy committee.
The frequency of regular meetings of the Pharmaceutical Affairs Committee determines how quickly new drugs enter the hospital 544px;text-align:right;text-indent:28px;">pharmacy 544px;text-align:right;text-indent:28px;">.
However, at present, most hospitals hold pharmacy meetings very frequently, generally once a year or once every six months.
This means that some of the negotiated drugs have passed the negotiation agreement period before they enter the hospital smoothly (the validity period of each negotiation of the National Medical Insurance Catalog is 2 years).
544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Photo: Liu Guoen, Dean of the Institute of Global Health Development of Peking University and Distinguished Professor of the National Development Institute Boya, delivered a speech at the symposium544px;text-align:right;text-indent:28px;">Photo: Liu Guoen, Dean of the Institute of Global Health Development of Peking University and Distinguished Professor of the National Development Institute Boya, delivered a speech at the symposium544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">In this regard, Liu Guoen, Dean of Peking University's Global Health Development Institute, Boya Distinguished Professor of the National Development Research Institute, and leader of the 2020 National Medical Insurance Catalog Negotiation Pharmacoeconomics Group, believes that “the zero-markup policy for drugs was based on the historical background of the time.
, Is imperative.
Of course, as a major public policy adjustment, it is inevitable to face the challenge of new problems.
Now it seems that the reverse problem of the zero markup system may be underestimated at that time-hospitals did reduce a lot of unnecessary However, it also reduces the motivation of hospitals to purchase and use clinically expensive drugs.
Looking into the future, further policy adjustments require more comprehensive consideration and comprehensive evaluation to avoid simple one-size-fits-all practices.
Reduce the risk of service subjects’ behavior from one extreme to the other.
”544px;text-align:right;text-indent:28px;">In this regard, Liu Guoen, Dean of Peking University's Global Health Development Institute, Boya Distinguished Professor of the National Development Research Institute, and leader of the 2020 National Medical Insurance Catalog Negotiation Pharmacoeconomics Group, believes that “the zero-markup policy for drugs was based on the historical background of the time.
, Is imperative.
Of course, as a major public policy adjustment, it is inevitable to face the challenge of new problems.
Now it seems that the reverse problem of the zero markup system may be underestimated at that time-hospitals did reduce a lot of unnecessary However, it also reduces the motivation of hospitals to purchase and use clinically expensive drugs.
Looking into the future, further policy adjustments require more comprehensive consideration and comprehensive evaluation to avoid simple one-size-fits-all practices.
Reduce the risk of service subjects’ behavior from one extreme to the other.
”544px;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-indent:0em;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Photo: Zhang Shu, member of the National Committee of the Chinese People's Political Consultative Conference and director of the Arrhythmia Center of Fuwai Hospital, Chinese Academy of Medical Sciences, delivered a speech at the symposium544px;text-align:right;text-indent:28px;">Photo: Zhang Shu, member of the National Committee of the Chinese People's Political Consultative Conference and director of the Arrhythmia Center of Fuwai Hospital, Chinese Academy of Medical Sciences, delivered a speech at the symposium544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">In the opinion of Zhang Shu, member of the National Committee of the Chinese People's Political Consultative Conference and director of the Arrhythmia Center of Fuwai Hospital of the Chinese Academy of Medical Sciences, this problem shows that many of us have not focused on the interests of patients-"Medical insurance wants to pay less, and hospitals want to generate more income.
At this stage, the interests of patients have not really been put in the first place.
This has caused many national policies to be changed in the implementation of the medical reform process.
"544px;text-align:right;text-indent:28px;">In the opinion of Zhang Shu, member of the National Committee of the Chinese People's Political Consultative Conference and director of the Arrhythmia Center of Fuwai Hospital of the Chinese Academy of Medical Sciences, this problem shows that many of us have not focused on the interests of patients-"Medical insurance wants to pay less, and hospitals want to generate more income.
At this stage, the interests of patients have not really been put in the first place.
This has caused many national policies to be changed in the implementation of the medical reform process.
"544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">"But we must also learn to look at problems with a long-term and developmental perspective.
China's medical reform will not be broken or established.
For example, the zero markup rate of medicines has eliminated the chronic diseases of the medical system in the past that relying on medicines to nourish doctors, but we still need to actively explore and establish new markets that meet Regular policies and supporting measures allow both doctors and patients to enjoy the dividends of China's economic development and medical system reform.
" Zhang Shu added.
544px;text-align:right;text-indent:28px;">"But we must also learn to look at problems with a long-term and developmental perspective.
China's medical reform will not be broken or established.
For example, the zero markup rate of medicines has eliminated the chronic diseases of the medical system in the past that relying on medicines to nourish doctors, but we still need to actively explore and establish new markets that meet Regular policies and supporting measures allow both doctors and patients to enjoy the dividends of China's economic development and medical system reform.
" Zhang Shu added.
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;text-indent:0em;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>031406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">
031406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">
031406px;height:1px;background:#15589F;color:#FFFFFF;overflow:hidden;">5px;background:#FFFFFF;transform:rotate(0deg);text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>Expert advice: multiple approaches to solve the problem of difficult admission of innovative drugs to hospitals and return to "patient-centered"Expert advice: multiple approaches to solve the problem of difficult admission of innovative drugs to hospitals and return to "patient-centered"544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">How to solve the difficult admission of innovative drugs? Yao Shukun believes that it is still necessary to set up a pharmaceutical service fee to compensate the service labor of the staff of the pharmacy department, change the status quo of "the hospital loses money as soon as the medicine is purchased", and fundamentally clear the problem of the hospital's "unable to prescribe and unwilling to prescribe" new drugs.
.
544px;text-align:right;text-indent:28px;">How to solve the difficult admission of innovative drugs? Yao Shukun believes that it is still necessary to set up a pharmaceutical service fee to compensate the service labor of the staff of the pharmacy department, change the status quo of "the hospital loses money as soon as the medicine is purchased", and fundamentally clear the problem of the hospital's "unable to prescribe and unwilling to prescribe" new drugs.
.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">"Since the financial pressure of the hospital has led to insufficient motivation to purchase new drugs, it is necessary to introduce a compensation mechanism for pharmacist services after the drug bonus is cancelled, such as the establishment of pharmacy service fees, etc.
, to share the hospital’s drug management costs and compensate the service value of pharmacists.
In this way, the enthusiasm of the main medical service personnel can be fully mobilized, so that while benefiting the broad masses of patients, it also benefits the medical staff so that they can serve patients without distraction.
" Yao Shukun said.
544px;text-align:right;text-indent:28px;">"Since the financial pressure of the hospital has led to insufficient motivation to purchase new drugs, it is necessary to introduce a compensation mechanism for pharmacist services after the drug bonus is cancelled, such as the establishment of pharmacy service fees, etc.
, to share the hospital’s drug management costs and compensate the service value of pharmacists.
In this way, the enthusiasm of the main medical service personnel can be fully mobilized, so that while benefiting the broad masses of patients, it also benefits the medical staff so that they can serve patients without distraction.
" Yao Shukun said.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">In fact, as early as the beginning of the "new medical reform" in 2009, many documents including the "Opinions of the Central Committee of the Communist Party of China and the State Council on Deepening the Reform of the Medical and Health System" and "Guiding Opinions on the Pilot Reform of Public Hospitals" have clearly stated that the establishment of pharmaceutical services To improve the compensation mechanism for public hospitals after the drug markup is cancelled.
544px;text-align:right;text-indent:28px;">In fact, as early as the beginning of the "new medical reform" in 2009, many documents including the "Opinions of the Central Committee of the Communist Party of China and the State Council on Deepening the Reform of the Medical and Health System" and "Guiding Opinions on the Pilot Reform of Public Hospitals" have clearly stated that the establishment of pharmaceutical services To improve the compensation mechanism for public hospitals after the drug markup is cancelled.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">At that time, many voices pointed out that zero drug addition is not a "panacea" for eradicating medicines to nourish doctors.
If a reasonable price mechanism is not established, the normal progress of all aspects of the medical reform will be affected.
544px;text-align:right;text-indent:28px;">At that time, many voices pointed out that zero drug addition is not a "panacea" for eradicating medicines to nourish doctors.
If a reasonable price mechanism is not established, the normal progress of all aspects of the medical reform will be affected.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">In an interview with the media in 2010, former deputy director of the Guangdong Provincial Department of Health, Liao Xinbo, he made a "divine prophecy": "The implementation of the basic drug system and the abolition of the use of medicines for medical care must be integrated with the government compensation system.
If not, it will be It affects the survival of the hospital and ultimately affects the patients to see a doctor.
” “Just cutting off the 15% of the drug bonus will not help at all.
If the current drug pricing mechanism is not changed, the entire medical reform may not achieve anything.
”544px;text-align:right;text-indent:28px;">In an interview with the media in 2010, former deputy director of the Guangdong Provincial Department of Health, Liao Xinbo, he made a "divine prophecy": "The implementation of the basic drug system and the abolition of the use of medicines for medical care must be integrated with the government compensation system.
If not, it will be It affects the survival of the hospital and ultimately affects the patients to see a doctor.
” “Just cutting off the 15% of the drug bonus will not help at all.
If the current drug pricing mechanism is not changed, the entire medical reform may not achieve anything.
”544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">However, the voice of the opposition is even more intense.
This kind of view believes that “the cancellation of drug additions and the payment of drug service fees are the'tails' of the new medical reform.
" Come and change, it is better to toss less!"544px;text-align:right;text-indent:28px;">However, the voice of the opposition is even more intense.
This kind of view believes that “the cancellation of drug additions and the payment of drug service fees are the'tails' of the new medical reform.
" Come and change, it is better to toss less!"544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">The pharmacy staff of the hospital, including Zhang Yi, director of the Department of Pharmacy of Beijing Tongren Hospital, appealed: “The pharmacy team of the hospital is an indispensable department, and it also needs to introduce and retain talents.
Those who study majors also provide professional technical services.
The Fudan University Hospital rankings also have clinical pharmacy professional settings.
Why can’t pharmacy services get reasonable returns and won’t be recognized by the society?”544px;text-align:right;text-indent:28px;">The pharmacy staff of the hospital, including Zhang Yi, director of the Department of Pharmacy of Beijing Tongren Hospital, appealed: “The pharmacy team of the hospital is an indispensable department, and it also needs to introduce and retain talents.
Those who study majors also provide professional technical services.
The Fudan University Hospital rankings also have clinical pharmacy professional settings.
Why can’t pharmacy services get reasonable returns and won’t be recognized by the society?”544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Suddenly, opinions were divergent.
Later, the addition of pharmaceutical service fees was shelved, and it became a historical issue.
544px;text-align:right;text-indent:28px;">Suddenly, opinions were divergent.
Later, the addition of pharmaceutical service fees was shelved, and it became a historical issue.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Liu Guoen said that there are two possible ways to improve the compensation mechanism after the establishment of a zero-markup response to drugs.
544px;text-align:right;text-indent:28px;">Liu Guoen said that there are two possible ways to improve the compensation mechanism after the establishment of a zero-markup response to drugs.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">The first is the reform path of administrative management/intervention, that is, the administrative department issues policies to make up for the lack of pharmaceutical service fees in the current medical services, and increase the enthusiasm of the hospital's pharmacy department staff to promote rational drug use management.
As for how much to make up, all parties negotiated and reached a consensus, and the government departments finally "finished".
544px;text-align:right;text-indent:28px;">The first is the reform path of administrative management/intervention, that is, the administrative department issues policies to make up for the lack of pharmaceutical service fees in the current medical services, and increase the enthusiasm of the hospital's pharmacy department staff to promote rational drug use management.
As for how much to make up, all parties negotiated and reached a consensus, and the government departments finally "finished".
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">The second is to adopt a management competition model.
In this model, the “management hand” of the government will not reach a particularly micro-specific level.
It will not control which drugs the hospital uses to treat a certain disease, and focus on scientific calculations and refined management.
The level of medical insurance payment at the level of population and type of disease in the service area, including community per capita payment, DRG payment method, grouped payment by type of disease, and so on.
"In this way, the importance of pharmacists can be significantly increased.
Existing empirical studies abroad have shown that giving full play to the role of pharmacists in clinical decision-making can greatly improve the treatment effect of patients and save the total medical expenses at the same time.
" Liu Guoen said To.
544px;text-align:right;text-indent:28px;">The second is to adopt a management competition model.
In this model, the “management hand” of the government will not reach a particularly micro-specific level.
It will not control which drugs the hospital uses to treat a certain disease, and focus on scientific calculations and refined management.
The level of medical insurance payment at the level of population and type of disease in the service area, including community per capita payment, DRG payment method, grouped payment by type of disease, and so on.
"In this way, the importance of pharmacists can be significantly increased.
Existing empirical studies abroad have shown that giving full play to the role of pharmacists in clinical decision-making can greatly improve the treatment effect of patients and save the total medical expenses at the same time.
" Liu Guoen said To.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">But what is certain is that both Path 1 and Path 2 will take time to achieve.
So, under the current system, how to solve the difficulty in hospital admission of innovative drugs?544px;text-align:right;text-indent:28px;">But what is certain is that both Path 1 and Path 2 will take time to achieve.
So, under the current system, how to solve the difficulty in hospital admission of innovative drugs?544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Yao Shukun believes that more successful local exploration programs can be referred to.
On the one hand, referring to the “Sichuan Practice”, we will implement separate payment for medicines negotiated through the national medical insurance, and will not be restricted by the control of the proportion of medicines, so as to solve the worries of hospitals for medicines and prescribing, and return to “patient-centered”.
544px;text-align:right;text-indent:28px;">Yao Shukun believes that more successful local exploration programs can be referred to.
On the one hand, referring to the “Sichuan Practice”, we will implement separate payment for medicines negotiated through the national medical insurance, and will not be restricted by the control of the proportion of medicines, so as to solve the worries of hospitals for medicines and prescribing, and return to “patient-centered”.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">Since 2019, the Sichuan Provincial Medical Insurance Bureau has opened a special channel for innovative drugs that have passed the negotiation of the National Medical Insurance Drug List.
For drugs that are expensive, specific to the user population, and relatively clear drug funds, single-line payment is implemented to provide a more convenient and efficient payment policy and reimbursement policy.
The medicines paid separately will be paid directly from the medical insurance fund in a certain proportion, regardless of outpatient and hospitalization and no deductible line.
At present, Sichuan Province has included 88 drugs that passed the “National Talks” in 2019 and 2020 into the category of single-line payment management.
544px;text-align:right;text-indent:28px;">Since 2019, the Sichuan Provincial Medical Insurance Bureau has opened a special channel for innovative drugs that have passed the negotiation of the National Medical Insurance Drug List.
For drugs that are expensive, specific to the user population, and relatively clear drug funds, single-line payment is implemented to provide a more convenient and efficient payment policy and reimbursement policy.
The medicines paid separately will be paid directly from the medical insurance fund in a certain proportion, regardless of outpatient and hospitalization and no deductible line.
At present, Sichuan Province has included 88 drugs that passed the “National Talks” in 2019 and 2020 into the category of single-line payment management.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">On the other hand, it is to introduce policies at the national level to encourage medical institutions to open up green channels for Class 1 new drugs to enter the hospital, reduce unnecessary procedures and restrictions, and quickly enter the clinic after the implementation of medical insurance in various provinces and cities.
544px;text-align:right;text-indent:28px;">On the other hand, it is to introduce policies at the national level to encourage medical institutions to open up green channels for Class 1 new drugs to enter the hospital, reduce unnecessary procedures and restrictions, and quickly enter the clinic after the implementation of medical insurance in various provinces and cities.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">At this point, Shanghai has a relatively successful practice.
In November 2018, Shanghai Ruijin Hospital established a special "drug special working group" around 17 anti-cancer drugs that were negotiated for entry into the national medical insurance.
After preliminary screening, 17 anti-cancer drugs that entered the medical insurance involved 12 departments.
Including the medical department, medical insurance office, pharmacy, outpatient office, computer center and other related departments.
On the first day of the formal implementation of the 17 anti-cancer drugs included in the Shanghai Medical Insurance Catalogue, the working group will be on standby at midnight.
If the patient is in urgent need but the drug is about to be out of supply, the relevant departments will record and report back to the working group in time.
The hospital coordinates with relevant departments to ensure that patients receive the "life-saving medicine" in a timely manner.
544px;text-align:right;text-indent:28px;">At this point, Shanghai has a relatively successful practice.
In November 2018, Shanghai Ruijin Hospital established a special "drug special working group" around 17 anti-cancer drugs that were negotiated for entry into the national medical insurance.
After preliminary screening, 17 anti-cancer drugs that entered the medical insurance involved 12 departments.
Including the medical department, medical insurance office, pharmacy, outpatient office, computer center and other related departments.
On the first day of the formal implementation of the 17 anti-cancer drugs included in the Shanghai Medical Insurance Catalogue, the working group will be on standby at midnight.
If the patient is in urgent need but the drug is about to be out of supply, the relevant departments will record and report back to the working group in time.
The hospital coordinates with relevant departments to ensure that patients receive the "life-saving medicine" in a timely manner.
544px;text-align:justify;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:right;text-indent:28px;">At the end of the symposium, the participating experts unanimously agreed that only by opening up the "last mile" for the use of Class 1 new drugs, can patients truly enjoy the benefit-benefit policy of the entry of innovative drugs into the national basic medical insurance catalog, and will also guide pharmaceutical companies to strengthen the research and development of new drugs.
, Promote clinical trials of new drugs, accelerate China's transformation from a major pharmaceutical country to a powerful pharmaceutical country, benefit the majority of patients, and help the early realization of "Healthy China 2030".
544px;text-align:right;text-indent:28px;">At the end of the symposium, the participating experts unanimously agreed that only by opening up the "last mile" for the use of Class 1 new drugs, can patients truly enjoy the benefit-benefit policy of the entry of innovative drugs into the national basic medical insurance catalog, and will also guide pharmaceutical companies to strengthen the research and development of new drugs.
, Promote clinical trials of new drugs, accelerate China's transformation from a major pharmaceutical country to a powerful pharmaceutical country, benefit the majority of patients, and help the early realization of "Healthy China 2030".